BioSpace News Archive

Bionomics Limited, a clinical-stage biopharmaceutical company, participated in the H.C Wainwright BioConnect Conference that was held virtually from January 10-13, 2022.

Stratus™ Medical, a company focused on advancing radiofrequency (RF) ablation treatment for chronic pain, announced three new patents today.

Evofem Biosciences, Inc. (NASDAQ: EVFM) today commended the Health Resources and Services Administration (HRSA) and the U.S. Department of Labor on their separately-issued updated guidance related to contraceptive access.

Novavax, Inc. and SK bioscience, Co. Limited announced that South Korea’s Ministry of Food and Drug Safety has approved a Biologics License Application from SK bioscience for Nuvaxovid™ COVID-19 Vaccine for active immunization in individuals 18 years of age and older for the prevention of COVID-19 caused by SARS-CoV-2.

Cellular Biomedicine Group Inc. announced that the Food and Drug Administration granted C-CAR039, a novel autologous bi-specific CAR-T therapy targeting both CD19 and CD20 antigens, both Regenerative Medicine Advanced Therapy Designation and Fast Track Designation for the treatment of patients with relapsed or refractory diffuse large B cell lymphoma.

Lantern Pharma announced it has expanded its collaboration agreement with the Developmental Therapeutics Branch of the National Cancer Institute of the National Institutes of Health.

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced plans to release its financial results for the fourth quarter and full year of 2021 on February 23, 2022 after the close of the financial markets.

Glytec, the only provider of cloud-based insulin management software across the continuum of care, announced a strategic partnership with Roche Diagnostics USA, a division of the world’s largest biotech company and a global pioneer in pharmaceuticals and diagnostics.

Targovax ASA announces that Innovation Norway has awarded Targovax an NOK 8.2m grant to accelerate product development activities related to the company’s TG mutant RAS vaccine program and planned clinical trials.

TCR 2 Therapeutics Inc. today announced the appointment of Rosemary Harrison, Ph.D., as Chief Business and Strategy Officer where she will be responsible for supporting a range of activities including commercial strategy, operational planning, corporate partnerships and long-term growth opportunities.